WARRENDALE, Pa., Aug. 7 /PRNewswire/ -- MEDRAD, INC., announced today the first installation of its Intego(TM) PET Infusion System at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. To achieve this milestone, MEDRAD has partnered with IBA Molecular which will supply UPMC with Fluorodeoxyglucose (FDG) in a multi-dose vial housed in a specially-designed Tungsten vial shield. Use of this innovative system minimizes the need to manually prepare and handle individual FDG doses, significantly reducing potential radiation exposure to hospital personnel.
The Intego System automates the administration of FDG for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures. By automating and controlling FDG dosing and infusion, the Intego System precisely, flexibly, safely, and easily administers FDG to patients throughout the day.
The Intego System automatically extracts a patient dose from a multi-dose vial and administers the dose, via infusion, directly to the patient, minimizing the need for manual dose preparation and associated handling, as well as protecting the technologist from the corresponding radiation exposure. With the Intego System's dose-on-demand capability, the prescribed dose may be administered when the patient and technologist are ready, enabling technologists to easily and efficiently respond to schedule changes, patient delays, and add-on patients.
"MEDRAD will improve the quality of healthcare for patients and will enhance procedure safety for clinicians at Intego's first clinical site, UPMC, Hillman Cancer Center. The partnership with IBA Molecular helps us achieve this part of our mission," said Doug Descalzi, executive director, MEDRAD Molecular Imaging.
"IBA is very pleased to support this first clinical installation of the Intego System. We are excited to be a part of improving the way FDG is delivered and administered. This innovation will improve safety for technologists and physicians performing Positron Emission Tomography," said Anwer Rizvi, president, IBA Molecular.
MEDRAD recently received U.S. FDA 510(k) clearance for the Intego PET Infusion System.
MEDRAD, INC., is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. For more information, visit http://www.medrad.com.
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.
About IBA Molecular
IBA Molecular is a committed partner in molecular imaging. Offering a global distribution of the most advanced cyclotron solutions, the most reliable radiopharmaceutical distribution network and the most novel research radionuclides, so that together we can make a difference in the lives of patients. Contact us to learn how our superior service, superior solutions and superior science can help build your PET business. http://www.iba-molecular.com
Cautionary statement regarding forward-looking statement.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC., undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
|SOURCE MEDRAD, INC.|
Copyright©2008 PR Newswire.
All rights reserved